Surveillance CT: Limit to 12 Months Posttherapy in Pediatric Advanced Hodgkin Lymphoma
Computed tomography (CT) imaging is overused for routine surveillance of children with advanced-stage Hodgkin’s lymphoma.
Diagnosis & Disease Information
No Significant PFS Difference Between BEACOPP, ABVD in Hodgkin Lymphoma
There was no significant difference in PFS between BEACOPP and ABVD regimens in patients with stage III-IV high-risk Hodgkin lymphoma, according to a phase 3 clinical trial presented at the 2012 American Association of Clinical Oncology Annual Meeting.
Post-Chemo Involved-Field RT Does Not Improve Overall Survival in Hodgkin Lymphoma
Event-free survival (EFS) but not overall survival (OS) significant for children and young adults with Hodgkin lymphoma who had a complete response to initial chemotherapy.
Obesity, Overweight at Diagnosis Ups B-Cell Lymphoma Prognosis
Improved survival for U.S. vets who are overweight, obese at diagnosis of diffuse large B-cell lymphoma.
Link Between Type 2 Diabetes and Hematological Cancer Risk Found
Diabetes mellitus type 2 seems to increase the risk of developing lymphoma, leukemia, and myeloma, but more studies are needed to solidify this link.
Brentuximab Vedotin Achieves Remission in Anaplastic Large-Cell Lymphoma Patients
Targeted therapy with brentuximab vedotin may be an effective treatment for relapsed or refractory systemic anaplastic large-cell lymphoma.
ASCO: Crizotinib Tolerated, Active in Pediatric Patients
Crizotinib active in anaplastic large cell lymphoma; neuroblastoma; other tumors with ALK mutations.
Protein Drives Tumorigenesis in B-Cell Tumors
CD19 is a major driver of tumorigenesis in B-cell tumors.
Less Intensive Chemotherapy Recommended for Advanced Stage Hodgkin Lymphoma
Six cycles of BEACOPPescalated chemotherapy — vs. 8 cycles — followed by PET-guided radiotherapy should be the treatment of choice for patients with advanced stage Hodgkin’s lymphoma.
G-CSF Primary Prophylaxis Not Cost Effective in Elderly Patients with DLBCL
Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) in elderly patients with diffuse large B-cell lymphoma (DLBCL) receiving curative-intent chemotherapy is not cost effective compared with secondary prophylaxis.
- Loading...
Loading...
Loading... 
Loading...